2,221
Views
2
CrossRef citations to date
0
Altmetric
Cognition

Centrally-acting anticholinergic drugs– associations with mortality, hospitalisation and cognitive decline following dementia diagnosis in people receiving antidepressant and antipsychotic drugs

, , , , , , ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 1747-1755 | Received 15 Mar 2021, Accepted 20 Jun 2021, Published online: 26 Jul 2021

References

  • Andrade, C. (2019). Anticholinergic drug exposure and the risk of dementia: There is modest evidence for an association but not for causality. The Journal of Clinical Psychiatry, 80, 19f13000.
  • Bishara, D., Harwood, D., Sauer, J., & Taylor, D. M. (2017). Anticholinergic effect on cognition (AEC) of drugs commonly used in older people. International Journal of Geriatric Psychiatry, 32(6), 650–656. https://doi.org/10.1002/gps.4507
  • Bishara, D., Perera, G., Harwood, D., Taylor, D., Sauer, J., Stewart, R., & Mueller, C. (2020). The anticholinergic effect on cognition (AEC) Scale: Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry, 35(9), 1069–1077. https://doi.org/10.1002/gps.5330
  • Coupland, C. A. C., Hill, T., Dening, T., Morriss, R., Moore, M., & Hippisley-Cox, J. (2019). Anticholinergic drug exposure and the risk of dementia: A nested case-control study. JAMA Internal Medicine, 179(8), 1084–1093. https://doi.org/10.1001/jamainternmed.2019.0677
  • Cunningham, H. (2002). GATE, a general architecture for text engineering. Computers and the Humanities, 36(2), 223–254. https://doi.org/10.1023/A:1014348124664
  • Folstein, M. F., Folstein, S. E., & Mchugh, P. R. (1975). Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189–198. https://doi.org/10.1016/0022-3956(75)90026-6
  • Fox, C., Livingston, G., Maidment, I. D., Coulton, S., Smithard, D. G., Boustani, M., & Katona, C. (2011a). The impact of anticholinergic burden in Alzheimer’s Dementia: The Laser-AD Study. Age and Ageing, 40(6), 730–735. https://doi.org/10.1093/ageing/afr102
  • Fox, C., Richardson, K., Maidment, I. D., Savva, G. M., Matthews, F. E., Smithard, D., Coulton, S., Katona, C., Boustani, M. A., & Brayne, C. (2011b). Anticholinergic medication use and cognitive impairment in the older population: The medical research council cognitive function and ageing study. Journal of the American Geriatrics Society, 59(8), 1477–1483. https://doi.org/10.1111/j.1532-5415.2011.03491.x
  • Jorge, R. E., Robinson, R. G., Arndt, S., & Starkstein, S. (2003). Mortality and poststroke depression: A placebo-controlled trial of antidepressants. American Journal of Psychiatry, 160(10), 1823–1829. https://doi.org/10.1176/appi.ajp.160.10.1823
  • Liang, K.-Y., & Zeger, S. L. (1986). Longitudinal data analysis using generalized linear models. Biometrika, 73(1), 13–22. https://doi.org/10.1093/biomet/73.1.13
  • Mcmichael, A. J., Zafeiridi, E., Ryan, M., Cunningham, E. L., Passmore, A. P., & Mcguinness, B. (2020). Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging & Mental Health, 1–8. https://doi.org/10.1080/13607863.2020.1830028
  • Monroe, T., & Carter, M. (2012). Using the Folstein Mini Mental State Exam (MMSE) to explore methodological issues in cognitive aging research. European Journal of Ageing, 9(3), 265–274. https://doi.org/10.1007/s10433-012-0234-8
  • Mueller, C., Huntley, J., Stubbs, B., Sommerlad, A., Carvalho, A. F., Perera, G., Stewart, R., & Veronese, N. (2017). Associations of neuropsychiatric symptoms and antidepressant prescription with survival in Alzheimer’s disease. Journal of the American Medical Directors Association, 18(12), 1076–1081. https://doi.org/10.1016/j.jamda.2017.07.001
  • Mueller, C., John, C., Perera, G., Aarsland, D., Ballard, C., & Stewart, R. (2020). Antipsychotic use in dementia: The relationship between neuropsychiatric symptom profiles and adverse outcomes. European Journal of Epidemiology, 36(1), 89–101.
  • Mueller, C., John, C., Perera, G., Aarsland, D., Ballard, C., & Stewart, R. (2021). Antipsychotic use in dementia: The relationship between neuropsychiatric symptom profiles and adverse outcomes. European Journal of Epidemiology, 36(1), 89–101. https://doi.org/10.1007/s10654-020-00643-2
  • Mueller, C., Molokhia, M., Perera, G., Veronese, N., Stubbs, B., Shetty, H., Codling, D., Huntley, J., & Stewart, R. (2018a). Polypharmacy in people with dementia: Associations with adverse health outcomes. Experimental Gerontology, 106, 240–245. https://doi.org/10.1016/j.exger.2018.02.011
  • Mueller, C., Perera, G., Hayes, R. D., Shetty, H., & Stewart, R. (2018b). Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer’s disease: A retrospective survival analysis. Age and Ageing, 47(1), 88–94. https://doi.org/10.1093/ageing/afx098
  • Noble, M., Mclennan, D., Wilkinson, K., Whitworth, A., Exley, S., Barnes, H., Dibben, C., & Mclennan, D. (2007). The English Indices of Deprivation, 2007. Unknown Publisher.
  • Oudshoorn, C. G. M., Buuren, S., & Rijckevorsel, J. L. A. (1999). Flexible multiple imputation by chained equations of the AVO-95 survey. TNO Prevention and Health Leiden.
  • Paton, C., & Ferrier, I. N. (2005). SSRIs and gastrointestinal bleeding. BMJ, 331(7516), 529–530. https://doi.org/10.1136/bmj.331.7516.529
  • Perera, G., Broadbent, M., Callard, F., Chang, C. K., Downs, J., Dutta, R., Fernandes, A., Hayes, R. D., Henderson, M., Jackson, R., Jewell, A., Kadra, G., Little, R., Pritchard, M., Shetty, H., Tulloch, A., & Stewart, R. (2016). Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: Current status and recent enhancement of an Electronic Mental Health Record-derived data resource. BMJ Open, 6(3), e008721. https://doi.org/10.1136/bmjopen-2015-008721
  • Perera, G., Khondoker, M., Broadbent, M., Breen, G., & Stewart, R. (2014). Factors associated with response to acetylcholinesterase inhibition in dementia: A cohort study from a secondary mental health care case register in London. PLOS One, 9(11), e109484. https://doi.org/10.1371/journal.pone.0109484
  • Richardson, K., Fox, C., Maidment, I., Steel, N., Loke, Y. K., Arthur, A., Myint, P. K., Grossi, C. M., Mattishent, K., Bennett, K., Campbell, N. L., Boustani, M., Robinson, L., Brayne, C., Matthews, F. E., & Savva, G. M. (2018). Anticholinergic drugs and risk of dementia: Case-control study. BMJ (Clinical Research ed.), 361, k1315. https://doi.org/10.1136/bmj.k1315
  • Rubin, D. B. (2004). Multiple imputation for nonresponse in surveys. John Wiley & Sons.
  • Saczynski, J. S., Beiser, A., Seshadri, S., Auerbach, S., Wolf, P. A., & Au, R. (2010). Depressive symptoms and risk of dementia: The Framingham Heart Study. Neurology, 75(1), 35–41. https://doi.org/10.1212/WNL.0b013e3181e62138
  • Stewart, R., Soremekun, M., Perera, G., Broadbent, M., Callard, F., Denis, M., Hotopf, M., Thornicroft, G., & Lovestone, S. (2009). The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: Development and descriptive data. BMC Psychiatry, 9, 51. https://doi.org/10.1186/1471-244X-9-51
  • Tan, E., Eriksdotter, M., García-Ptacek, S., Fastbom, J., & Johnell, K. (2018). Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer’s Disease, 65(2), 588–589. https://doi.org/10.3233/JAD-180353
  • Taylor, C. B., Youngblood, M. E., Catellier, D., Veith, R. C., Carney, R. M., Burg, M. M., Kaufmann, P. G., Shuster, J., Mellman, T., Blumenthal, J. A., Krishnan, R., Jaffe, A. S., & ENRICHD Investigators. (2005). Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Archives of General Psychiatry, 62(7), 792–798. https://doi.org/10.1001/archpsyc.62.7.792
  • Tsamakis, K., Gadelrab, R., Wilson, M., Bonnici-Mallia, A. M., Hussain, L., Perera, G., Rizos, E., Das-Munshi, J., Stewart, R., & Mueller, C. (2021). Dementia in people from ethnic minority backgrounds: Disability, functioning, and pharmacotherapy at the time of diagnosis. Journal of the American Medical Directors Association, 22(2), 446–452. https://doi.org/10.1016/j.jamda.2020.06.026